Therapy Areas: AIDS & HIV
Global Cryptococcosis Market to Reach USD 6.7bn by 2025, Research and Markets Forecasts
18 September 2017 - - The global Cryptococcosis market was valued at USD 4.51bn in 2016, and is expected to reach USD 6.76bn by 2025, expanding at a CAGR of 4.5% from 2017 to 2025, according...
Bristol-Myers Squibb Touts Positive Study Data for Opdivo, Yervoy Combination in Advanced or Metastatic Renal Cell Carcinom
12 September 2017 - - New York, New York-based biopharmaceutical company Bristol-Myers Squibb (NYSE: BMY) has provided results from the Phase 3 CheckMate -214 trial evaluating Opdivo (nivolumab) plus ...
Bristol-Myers Squibb, Pfizer Report Findings from Study of Eliquis (apixaban) in Non-Valvular Atrial Fibrillation Undergoing Cardioversion
29 August 2017 - - New York, New York-based biopharmaceutical company Bristol-Myers Squibb (NYSE: BMY) New York, New York-based biopharmaceutical and healthcare products specialist Pfizer Inc. (NYSE: ...
Otsuka and Mylan agree licence deal for tuberculosis treatment
24 August 2017 - Japan-based Otsuka Pharmaceutical Co Ltd and global generic and speciality pharmaceutical company Mylan NV (NASDAQ: MYL) have entered into a licence agreement involving their respecti...
Aurobindo Pharma gets tentative FDA approval for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets
21 August 2017 - India-based Aurobindo Pharma (NSE: AUROPHARMA) has been granted tentative approval by the US Food and Drug Administration (FDA) for dolutegravir, lamivudine and tenofovir disoproxil f...
IHI Partners with South Africa National Department of Health on Initiative to Improve Tuberculosis Care, Outcomes
21 August 2017 - - US-based health and health care improvement group The Institute for Healthcare Improvement (IHI) has been awarded a USD 3m grant from the Bill and Melinda Gates Foundation...